Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening

The editorialists discuss the limitations of Patel and colleagues' study, which estimated the prevalence of elevated atherosclerotic risk among nondiabetic adults younger than 50 years. They also discuss why the primary prevention of cardiovascular disease should include early-life evaluation of low-density lipoprotein cholesterol, not a delayed approach.

http://ift.tt/2pOYXoa